Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of novel therapeutics for the treatment of profound neuropsychiatric disorders, with particular emphasis on applications for children. Our lead product candidate is a synthetic version of the neuroactive peptide secretin for profound social deficits. Secretin is currently in a Phase 2 clinical trial for the treatment of the "negative" (i.e. social) symptoms of schizophrenia and planning is underway for clinical trials in an anxiety disorder in the second half of 2004. There are approximately 2 million people in the United States with schizophrenia. Repligen also has ongoing clinical programs evaluating Uridine for neurological disorders, and CTLA4-Ig (a monoclonal antibody) for autoimmune diseases.
Repligen has a specialty pharmaceuticals business comprised of rProtein A and SecreFlo, the profits from which will be used to maintain financial stability and to help fund the development of our proprietary products. SecreFlo, secretin for injection, is marketed to gastroenterologists for pancreatic assessment and for use during a gastrointestinal procedure called ERCP and rProtein A is a consumable reagent used by the pharmaceutical industry to produce a class of drugs called monoclonal antibodies.
Contact us
Contact：
Phone：
1-800-622-2259
Mobile phone：
(800) 622-2259
Fax：
1-781-250-0115
Website：
http://www.repligen.com/
Zip Code：
Address：
RepliGen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, MA 02453
Search Product